WuXi PharmaTech reported Q3 revenues were up 18% to $173.6 million, a record, while GAAP earnings were higher by a smaller 8% at $0.45. The company has "strong momentum," according to Dr. Ge Li, Chairman and CEO. To keep growing, it increased Capital Expenditures from $56 million last year to $100 million in 2014, and will spend even more next year to increase manufacturing capacity, WuXi's fastest growing business sector. And WuXi now has 500 employees devoted to biologic drug discovery, another major growth area.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
